Table 2.

The prognostic value of clinicopathological factors and RUNX3 site-specific hypermethylation in multivariate Cox regression analysis

Variables	RUNX3 gene
	CpG site -1397		CpG site -1406		CpG site -1415		CpG site -1417
	Hazard Ratio (HR) (95% CI)	P	Hazard Ratio (HR) (95% CI)	P	Hazard Ratio (HR) (95% CI)	P	Hazard Ratio (HR) (95% CI)	P
Methylation levels
< cut-off values	1.00 (reference)		1.00 (reference)		1.00 (reference)		1.00 (reference)
≥ cut-off values	5.83 (1.66-20.44)	0.006	16.92 (4.42-64.76)	0.000	8.06 (2.47-26.27)	0.001	12.69 (2.94-54.69)	0.001
Gender
Female	1.00 (reference)		1.00 (reference)		1.00 (reference)		1.00 (reference)
Male	0.53 (0.13-2.26)	0.39	0.94 (0.24-3.72)	0.93	0.75 (0.20-2.85)	0.67	1.15 (0.29-4.57)	0.85
Age
≤ 40	1.00 (reference)		1.00 (reference)		1.00 (reference)		1.00 (reference)
> 40	0.11 (0.01-0.93)	0.04	0.26 (0.04-1.84)	0.18	0.21 (0.03-1.56)	0.13	0.27 (0.03-2.23)	0.23
Lymph node metastasis
No	1.00 (reference)		1.00 (reference)		1.00 (reference)		1.00 (reference)
Yes	2.72 (0.66-11.24)	0.17	4.60 (1.08-19.72)	0.04	3.81 (0.91-16.00)	0.07	3.61 (0.96-13.68)	0.06
TNM Stage
< III	1.00 (reference)		1.00 (reference)		1.00 (reference)		1.00 (reference)
≥ III	5.11 (0.75-34.93)	0.09	1.82 (0.34-9.61)	0.48	1.67 (0.31-9.07)	0.55	0.71 (0.10-4.95)	0.73